跳至主要内容
临床试验/CTRI/2022/11/047511
CTRI/2022/11/047511尚未招募未知

A prospective, observational study to compare the patient reported outcomes with the use of oral dydrogesterone vs. micronized vaginal progesterone in high risk pregnancies (PERCEPT study) - PERCEPT

Emcure Pharmaceuticals Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1.Pregnant women with age of >= 18 years and who are ready to give informed consent for participation in the study.
  • 2.Women with clinically diagnosed pregnancy of <= 12 weeks of gestation and visiting department of obstetrics and gynecology.
  • 3.History of more than two miscarriages and/or presenting with vaginal bleeding
  • 4.Patient suitable for treatment with micronized vaginal progesterone or dydrogesterone therapy based on locally approved prescribing information.

排除标准

  • 1.Pregnant women who have contraindications for use of micronized vaginal progesterone or dydrogesterone.
  • 2.Any condition that, in the opinion of the investigator, does not justify the patientâ??s inclusion in the study.

研究者

相似试验